华尔街给Haleon带来了好坏参半的评级,引用了强劲的消费者健康产品和新兴市场增长,但注意到定价和竞争方面的关切。 Wall Street gives Haleon mixed ratings, citing strong consumer health products and emerging market growth, but noting pricing and competition concerns.

华尔街分析师对Haleon plc(HLN)的评级有好有坏,有些人表示谨慎乐观,因为该公司在消费者健康方面的投资组合雄厚,其战略重点是新兴市场,而另一些人则强调对定价压力和关键产品类别的竞争挑战的关切。 Wall Street analysts have issued mixed ratings on Haleon plc (HLN), with some expressing cautious optimism due to the company’s strong portfolio in consumer health and its strategic focus on emerging markets, while others highlight concerns over pricing pressures and competitive challenges in key product categories. 最近的收入报告显示,收入增长不大,利润幅度增加,支持了机构投资者的适度购买情绪。 Recent earnings reports show modest revenue growth and improved margins, supporting a moderate buy sentiment among institutional investors.